PT2970303T - Xantinas substituídas e métodos de sua utilização - Google Patents

Xantinas substituídas e métodos de sua utilização

Info

Publication number: PT2970303T
Authority: PT; Portugal
Prior art keywords: methods; substituted xanthines; xanthines; substituted
Prior art date: 2013-03-15

Application number

PT147224521T

Other languages

English (en)

Inventor

Chenard Bertrand

Gallaschun Randall

Original Assignee

Hydra Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-15

Filing date

2014-03-14

Publication date

2017-06-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50680155&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2970303(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-14 Application filed by Hydra Biosciences Inc filed Critical Hydra Biosciences Inc

2017-06-23 Publication of PT2970303T publication Critical patent/PT2970303T/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Epidemiology (AREA)
Thiazole And Isothizaole Compounds (AREA)
Medicinal Preparation (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Silver Salt Photography Or Processing Solution Therefor (AREA)

PT147224521T 2013-03-15 2014-03-14 Xantinas substituídas e métodos de sua utilização PT2970303T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201361789724P	2013-03-15	2013-03-15

Publications (1)

Publication Number	Publication Date
PT2970303T true PT2970303T (pt)	2017-06-23

Family

ID=50680155

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT147224521T PT2970303T (pt)	2013-03-15	2014-03-14	Xantinas substituídas e métodos de sua utilização

Country Status (32)

Country	Link
US (6)	US9359359B2 (pt)
EP (1)	EP2970303B3 (pt)
JP (1)	JP6360149B2 (pt)
KR (1)	KR102227629B1 (pt)
CN (2)	CN105143229B (pt)
AU (1)	AU2014228206C1 (pt)
CA (1)	CA2899646C (pt)
CL (1)	CL2015002738A1 (pt)
CY (1)	CY1119042T1 (pt)
DK (1)	DK2970303T6 (pt)
EA (1)	EA028815B1 (pt)
ES (1)	ES2636835T7 (pt)
HK (1)	HK1217329A1 (pt)
HR (1)	HRP20170840T4 (pt)
HU (1)	HUE033528T4 (pt)
IL (1)	IL240216B (pt)
LT (1)	LT2970303T (pt)
MX (1)	MX370372B (pt)
MY (1)	MY189912A (pt)
NZ (1)	NZ711718A (pt)
PE (1)	PE20151779A1 (pt)
PH (1)	PH12015502141B1 (pt)
PL (1)	PL2970303T6 (pt)
PT (1)	PT2970303T (pt)
RS (1)	RS56066B2 (pt)
SG (1)	SG11201506479TA (pt)
SI (1)	SI2970303T1 (pt)
TW (1)	TWI609867B (pt)
UA (1)	UA117470C2 (pt)
UY (1)	UY35488A (pt)
WO (1)	WO2014143799A2 (pt)
ZA (1)	ZA201505414B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8173750B2 (en)	2009-04-23	2012-05-08	ATRP Solutions, Inc.	Star macromolecules for personal and home care
CN105143229B (zh)	2013-03-15	2017-06-30	海德拉生物科学有限公司	取代的黄嘌呤及其使用方法
WO2016023831A1 (en) *	2014-08-11	2016-02-18	Hydra Biosciences, Inc.	Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
GB2553685B (en)	2015-03-27	2020-06-10	Latvian Inst Organic Synthesis	Novel ethynylxanthines for use as inhibitors of matrix metalloproteinases and angiogenesis
CA2989161C (en)	2015-03-27	2022-03-01	Latvian Institute Of Organic Synthesis	Ethynylxanthines, preparation and use for cancer treatment
WO2016159747A1 (en)	2015-03-27	2016-10-06	Latvian Institute Of Organic Synthesis	Ethynylxanthines, preparation and use as calcium ion channel modulators
EP3280417B1 (en) *	2015-04-08	2020-07-29	Lewis and Clark Pharmaceuticals, Inc.	Xanthine-substituted alkynyl carbamates/reverse carbamates as a2b antagonists
CN107118586A (zh) *	2016-02-24	2017-09-01	中国科学技术大学	含氮杂环基取代的烯类化合物的用途
GB201702160D0 (en) *	2017-02-09	2017-03-29	Univ Leeds Innovations Ltd	Inhibitors for use in therapy
US11666577B2 (en) *	2017-02-28	2023-06-06	National Institute Of Biological Sciences, Beijing	MLKL inhibitors
CN110573509B (zh) *	2017-02-28	2023-05-26	北京生命科学研究所	Mlkl抑制剂
CN110997675B (zh) *	2017-07-11	2022-06-07	勃林格殷格翰国际公司	新的取代的黄嘌呤衍生物
US11623930B2 (en)	2018-03-05	2023-04-11	Goldfinch Bio, Inc.	Imidazodiazepinediones and methods of use thereof
CN113166150B (zh) *	2018-12-12	2023-12-01	勃林格殷格翰国际有限公司	经取代的黄嘌呤衍生物
HUE064908T2 (hu)	2018-12-12	2024-04-28	Boehringer Ingelheim Int	Szubsztituált xantinszármazékok
CN112979651B (zh) *	2021-04-09	2022-02-01	南京纽邦生物科技有限公司	一种副黄嘌呤的制备方法
CN113354646B (zh) *	2021-07-06	2022-11-15	南开大学	8-芳氧基烷氧基取代黄嘌呤衍生物及其制备方法和应用
CN115636831A (zh) *	2022-10-27	2023-01-24	中国药科大学	稠合嘧啶二酮类化合物、其用途以及药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4304650A1 (de) *	1993-02-16	1994-08-18	Thomae Gmbh Dr K	Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6878715B1 (en) *	1994-02-18	2005-04-12	Cell Therapeutics, Inc.	Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
JP4191269B2 (ja)	1996-05-17	2008-12-03	興和株式会社	新規なアニリド化合物及びこれを含有する医薬
JPH10318487A (ja)	1997-05-16	1998-12-04	Mitsubishi Gas Chem Co Inc	真空断熱材用ゲッタ
US6075029A (en) *	1998-01-02	2000-06-13	Cell Therapeutics, Inc.	Xanthine modulators of metabolism of cellular P-450
US6187780B1 (en) *	1998-04-16	2001-02-13	Boehringer Ingelheim Pharma Kg	Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
DE60024604T2 (de) *	1999-04-09	2006-08-24	Cell Therapeutics, Inc., Seattle	Xanthinderivate und analoge als zellsignalisierung inhibitoren
KR20030014394A (ko) *	2000-07-04	2003-02-17	노보 노르디스크 에이/에스	효소 ｄｐｐ-ｉｖ의 억제제인 헤테로고리 화합물
NZ526336A (en)	2000-12-07	2004-11-26	Cv Therapeutics Inc	Substituted 1, 3,5-triazines and pyrimidines as ABCA-1 elevating compounds against coronary artery disease or atherosclerosis
SK288003B6 (sk) *	2001-02-24	2012-10-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthin derivatives, method for the preparation thereof, pharmaceutical composition containing thereof and their use
CN100467469C (zh) *	2001-11-09	2009-03-11	Cv医药有限公司	A2b腺苷受体拮抗剂
AU2003249604B2 (en) *	2003-05-06	2011-06-30	Gilead Sciences, Inc.	A2B adenosine receptor antagonists
JP2007511528A (ja)	2003-11-13	2007-05-10	ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム	心肥大および心不全の処置としてのｔｒｐチャネル阻害方法
EP1841448A2 (en)	2004-12-30	2007-10-10	Diakine Therapeutics, Inc.	Pharmaceutical compositions and methods for restoring beta-cell mass and function
US8143254B2 (en)	2005-02-18	2012-03-27	Cornell Research Foundation, Inc.	Methods for modulating ion channels
EP1912992A1 (en) *	2005-08-10	2008-04-23	SmithKline Beecham Corporation	Xanthine derivatives as selective hm74a agonists
DE602006012694D1 (de) *	2005-09-06	2010-04-15	Glaxosmithkline Llc	Benzimidazolthiophenverbindungen als plk-modulatoren
WO2007065595A2 (en) *	2005-12-07	2007-06-14	Ucb Pharma, S.A.	Xanthine derivatives, processes for preparing them and their uses
JP5858557B2 (ja) *	2005-12-22	2016-02-10	ハイドラバイオサイエンシズインコーポレイテッドＨｙｄｒａＢｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ．	疼痛を処置するためのｔｒｐａ１阻害剤
US20070232673A1 (en)	2006-01-19	2007-10-04	Roth Gregory P	2-Imino-benzimidazoles
WO2007101213A2 (en)	2006-02-28	2007-09-07	Kalypsys, Inc.	Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors
US20090269313A1 (en) *	2006-07-19	2009-10-29	Diakine Therapeutics, Inc.	Encapsulation system
WO2009157938A1 (en) *	2008-06-26	2009-12-30	Cv Therapeutics, Inc.	A2b adenosine receptor antagonists for treating cancer
EP2467398B1 (en)	2009-08-20	2019-10-09	Poseida Therapeutics, Inc.	Trpc4 inhibitors and uses thereof
WO2011114184A1 (en) *	2010-03-15	2011-09-22	Glenmark Pharmaceuticals S.A.	Amides of heterocyclic compounds as trpa1 inhibitors
WO2012050641A2 (en)	2010-06-08	2012-04-19	Hydra Biosciences, Inc	Use of trpa1 antagonists to prevent or treat infections caused by biological-warfare agents
JP2013023102A (ja)	2011-07-22	2013-02-04	Panasonic Corp	列車情報提供システム
RU2014108885A (ru)	2011-08-09	2015-09-20	Хайдра Байосайенсиз, Инк.	Ингибирование транзиторного рецепторного потенциала ионного канала trpa1
CN103121970B (zh)	2012-12-04	2015-04-29	中国科学院昆明植物研究所	苯并咪唑及其衍生物，其药物组合物及其在制备抗抑郁药物中的应用
CN105143229B (zh)	2013-03-15	2017-06-30	海德拉生物科学有限公司	取代的黄嘌呤及其使用方法

2014
- 2014-03-14 CN CN201480023267.0A patent/CN105143229B/zh active Active
- 2014-03-14 DK DK14722452.1T patent/DK2970303T6/en active
- 2014-03-14 EA EA201591615A patent/EA028815B1/ru not_active IP Right Cessation
- 2014-03-14 ES ES14722452.1T patent/ES2636835T7/es active Active
- 2014-03-14 SI SI201430241T patent/SI2970303T1/sl unknown
- 2014-03-14 LT LTEP14722452.1T patent/LT2970303T/lt unknown
- 2014-03-14 RS RS20170566A patent/RS56066B2/sr unknown
- 2014-03-14 PE PE2015001829A patent/PE20151779A1/es active IP Right Grant
- 2014-03-14 NZ NZ711718A patent/NZ711718A/en unknown
- 2014-03-14 CA CA2899646A patent/CA2899646C/en active Active
- 2014-03-14 TW TW103109651A patent/TWI609867B/zh active
- 2014-03-14 UA UAA201507774A patent/UA117470C2/uk unknown
- 2014-03-14 US US14/210,781 patent/US9359359B2/en active Active
- 2014-03-14 EP EP14722452.1A patent/EP2970303B3/en active Active
- 2014-03-14 JP JP2016502662A patent/JP6360149B2/ja active Active
- 2014-03-14 PL PL14722452T patent/PL2970303T6/pl unknown
- 2014-03-14 KR KR1020157029667A patent/KR102227629B1/ko active IP Right Grant
- 2014-03-14 MX MX2015011617A patent/MX370372B/es active IP Right Grant
- 2014-03-14 WO PCT/US2014/027920 patent/WO2014143799A2/en active Application Filing
- 2014-03-14 PT PT147224521T patent/PT2970303T/pt unknown
- 2014-03-14 CN CN201710063554.XA patent/CN107082782B/zh active Active
- 2014-03-14 AU AU2014228206A patent/AU2014228206C1/en active Active
- 2014-03-14 MY MYPI2015702631A patent/MY189912A/en unknown
- 2014-03-14 HU HUE14722452A patent/HUE033528T4/en unknown
- 2014-03-14 SG SG11201506479TA patent/SG11201506479TA/en unknown
- 2014-03-17 UY UY0001035488A patent/UY35488A/es active IP Right Grant
2015
- 2015-07-28 ZA ZA2015/05414A patent/ZA201505414B/en unknown
- 2015-07-29 IL IL240216A patent/IL240216B/en active IP Right Grant
- 2015-09-15 PH PH12015502141A patent/PH12015502141B1/en unknown
- 2015-09-15 CL CL2015002738A patent/CL2015002738A1/es unknown
2016
- 2016-04-25 US US15/137,327 patent/US20160237089A1/en not_active Abandoned
- 2016-05-10 HK HK16105298.0A patent/HK1217329A1/zh unknown
2017
- 2017-06-01 HR HRP20170840TT patent/HRP20170840T4/hr unknown
- 2017-06-14 US US15/622,838 patent/US9969736B2/en active Active
- 2017-06-20 CY CY20171100647T patent/CY1119042T1/el unknown
2018
- 2018-05-02 US US15/968,941 patent/US10399982B2/en active Active
2019
- 2019-04-29 US US16/397,697 patent/US11208409B2/en active Active
2021
- 2021-11-10 US US17/523,838 patent/US11958854B2/en active Active

Also Published As

Publication number	Publication date
MX2015011617A (es)	2016-04-25
US20190322667A1 (en)	2019-10-24
CN105143229A (zh)	2015-12-09
DK2970303T5 (en)	2018-01-02
CN107082782A (zh)	2017-08-22
JP6360149B2 (ja)	2018-07-18
CA2899646A1 (en)	2014-09-18
SI2970303T1 (sl)	2017-08-31
CN107082782B (zh)	2020-03-20
PE20151779A1 (es)	2015-11-20
EP2970303B9 (en)	2017-09-20
US20180244674A1 (en)	2018-08-30
KR20150133233A (ko)	2015-11-27
CL2015002738A1 (es)	2016-06-10
ES2636835T7 (es)	2018-11-20
UY35488A (es)	2014-10-31
MX370372B (es)	2019-12-11
CN105143229B (zh)	2017-06-30
TWI609867B (zh)	2018-01-01
US11208409B2 (en)	2021-12-28
US9359359B2 (en)	2016-06-07
US20160237089A1 (en)	2016-08-18
EP2970303B3 (en)	2018-08-01
US20170305910A1 (en)	2017-10-26
AU2014228206A1 (en)	2015-09-24
TW201533044A (zh)	2015-09-01
US11958854B2 (en)	2024-04-16
HUE033528T2 (hu)	2017-12-28
BR112015021164A2 (pt)	2017-07-18
RS56066B2 (sr)	2018-09-28
US20230040259A1 (en)	2023-02-09
WO2014143799A4 (en)	2015-02-12
EA028815B1 (ru)	2018-01-31
EA201591615A1 (ru)	2016-05-31
EP2970303B1 (en)	2017-05-10
HUE033528T4 (en)	2018-05-02
EP2970303A2 (en)	2016-01-20
JP2016513717A (ja)	2016-05-16
IL240216A0 (en)	2015-09-24
AU2014228206C1 (en)	2018-10-25
PH12015502141A1 (en)	2016-01-25
SG11201506479TA (en)	2015-09-29
KR102227629B1 (ko)	2021-03-16
RS56066B1 (sr)	2017-10-31
AU2014228206B2 (en)	2018-05-10
IL240216B (en)	2018-11-29
NZ711718A (en)	2020-05-29
WO2014143799A9 (en)	2014-12-24
BR112015021164A8 (pt)	2019-12-03
DK2970303T6 (en)	2018-10-08
MY189912A (en)	2022-03-21
UA117470C2 (uk)	2018-08-10
ZA201505414B (en)	2016-03-30
PL2970303T3 (pl)	2017-08-31
US20140275071A1 (en)	2014-09-18
PH12015502141B1 (en)	2016-01-25
HRP20170840T4 (hr)	2018-11-16
US9969736B2 (en)	2018-05-15
HRP20170840T1 (hr)	2017-09-08
PL2970303T6 (pl)	2018-12-31
US10399982B2 (en)	2019-09-03
LT2970303T (lt)	2017-07-25
CY1119042T1 (el)	2018-01-10
CA2899646C (en)	2021-08-31
ES2636835T3 (es)	2017-10-09
WO2014143799A3 (en)	2014-11-06
WO2014143799A2 (en)	2014-09-18
HK1217329A1 (zh)	2017-01-06
DK2970303T3 (en)	2017-06-26

Publication	Publication Date	Title
HRP20170840T4 (hr)	2018-11-16	Supstituirani ksantini i metode njihove uporabe
IL290547A (en)	2022-04-01	Antibodies and methods of use
IL244495B (en)	2020-06-30	Anti-alpha-synuclein antibodies and methods of use
GB2535360B (en)	2017-04-12	Methods of preparing polyhemiaminals and polyhexahydrotriazines
SG11201600028YA (en)	2016-02-26	Substituted aminopyrimidine compounds and methods of use
HK1225612A1 (zh)	2017-09-15	抗ly6e抗體及使用方法
HK1224307A1 (zh)	2017-08-18	原毒素- 變體及其使用方法
HK1218247A1 (zh)	2017-02-10	益生菌和使用方法
IL245272A0 (en)	2016-06-30	pif-transfected cells and methods of use